NVE Corp Dossier - Source-backed chat

NVE Corp

NVECNASDAQ

SectorInformation Technology

IndustrySemiconductors

Beta (adjusted)1.23

Intrinsic Value $38.73median of 4 methods · middle span $33-$45based on filings through 30 Jun 2026

Market Price $110.80Price as of 1 Oct 2026

Significantly overvaluedIntrinsic value is 65% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (-65%)

Data confidence Sign in to view data confidence

Market Cap $536M

Enterprise Value $533.1M

Shares Outstanding 4.8M diluted

Moat Rating Wide

Next Earnings Date26 Oct 2026

Last ex-dividend3 Aug 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

NVE Corporation (NVEC) is a highly profitable, debt-free niche leader in spintronics nanotechnology, specializing in high-performance sensors and couplers. The company boasts exceptional gross margins (~79%) and a robust cash-return policy, paying a consistent $4.00 annual dividend. However, top-line growth remains modest (1.8% in FY2026), and the business faces significant customer concentration risks. While its strong balance sheet and advanced technology provide a solid floor, the lack of near-term high-growth catalysts justifies a Hold rating.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

A downturn in industrial automation or a reduction in orders from key medical customers (e.g., Abbott Laboratories) leads to a contraction in product sales. Increased reliance on lower-margin distributor channels further compresses gross margins toward 75%, threatening dividend coverage from operating cash flows.

Base CaseCentral scenario

NVE maintains its stable market share in industrial and medical spintronic sensors, with product sales growing at a low-single-digit rate. Gross margins stabilize around 78-80%, and the company continues to distribute its strong cash flows via its $4.00 annual dividend, supported by its massive cash and marketable securities reserves.

Bull CaseUpside scenario

NVE Corp is poised for significant growth driven by the commercial acceleration of its proprietary spintronics technology. Key catalysts include: (1) Strong demand and secular tailwinds in high-growth end markets such as advanced robotics, industrial AIoT, and data centers, where its ultra-low-power, high-sensitivity sensors and couplers offer a massive performance edge over legacy silicon. (2) The launch of highly differentiated, miniaturized wafer-level chip-scale packaging (WLCSP) sensors, including its first-of-its-kind MRI-safe sensors (stable up to 9 Tesla) for implantable medical devices. Once qualified into FDA-approved Class 3 medical devices, these sensors create highly defensible, high-margin, and sticky revenue streams. (3) Exceptional financial strength characterized by a debt-free balance sheet, over $40 million in cash and marketable securities, elite gross margins exceeding 80%, and a strong capital return program highlighted by a consistent $1.00 quarterly dividend.

Scenarios reflect our research view at the research date.

Key Investment Merits

Pristine balance sheet with zero debt and over $43 million in cash and marketable securities (representing ~69% of total assets).
Industry-leading profitability with gross margins of 78.7% and net margins of 54% in Q3 FY2026.
Strong shareholder alignment through a high dividend yield, supported by consistent cash generation.

Key Investment Risks

High customer concentration, particularly in the medical device sector (e.g., Abbott Laboratories).
Slow organic revenue growth (1.8% in FY2026) relative to the broader semiconductor industry.
Gross margin compression driven by a shift toward lower-margin distributor sales channels.

Thesis Invalidation Triggers

Termination or material negative modification of the Supplier Partnering Agreement with Abbott Laboratories.
A sustained drop in gross margins below 75%.
Reduction or suspension of the quarterly $1.00 per share dividend.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.